000128032 001__ 128032
000128032 005__ 20240228145530.0
000128032 0247_ $$2doi$$a10.1093/neuonc/nox027
000128032 0247_ $$2pmid$$apmid:28371821
000128032 0247_ $$2pmc$$apmc:PMC5570194
000128032 0247_ $$2ISSN$$a1522-8517
000128032 0247_ $$2ISSN$$a1523-5866
000128032 0247_ $$2altmetric$$aaltmetric:18480588
000128032 037__ $$aDKFZ-2017-04054
000128032 041__ $$aeng
000128032 082__ $$a610
000128032 1001_ $$aGojo, Johannes$$b0
000128032 245__ $$aTelomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
000128032 260__ $$aOxford$$bOxford Univ. Press$$c2017
000128032 3367_ $$2DRIVER$$aarticle
000128032 3367_ $$2DataCite$$aOutput Types/Journal article
000128032 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533901012_25145
000128032 3367_ $$2BibTeX$$aARTICLE
000128032 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128032 3367_ $$00$$2EndNote$$aJournal Article
000128032 520__ $$aEpendymomas account for up to 10% of childhood CNS tumors and have a high rate of tumor recurrence despite gross total resection. Recently, classification into molecular ependymoma subgroups has been established, but the mechanisms underlying the aggressiveness of certain subtypes remain widely enigmatic. The aim of this study was to dissect the clinical and biological role of telomerase reactivation, a frequent mechanism of cancer cells to evade cellular senescence, in pediatric ependymoma.We determined telomerase enzymatic activity, hTERT mRNA expression, promoter methylation, and the rs2853669 single nucleotide polymorphism located in the hTERT promoter in a well-characterized cohort of pediatric intracranial ependymomas.In posterior fossa ependymoma group A (PF-EPN-A) tumors, telomerase activity varied and was significantly associated with dismal overall survival, whereas telomerase reactivation was present in all supratentorial RelA fusion-positive (ST-EPN-RELA) ependymomas. In silico analysis of methylation patterns showed that only these two subgroups harbor hypermethylated hTERT promoters suggesting telomerase reactivation via epigenetic mechanisms. Furthermore, chromosome 1q gain, a well-known negative prognostic factor, was strongly associated with telomerase reactivation in PF-EPN-A. Additional in silico analyses of gene expression data confirmed this finding and further showed enrichment of the E-twenty-six factor, Myc, and E2F target genes in 1q gained ependymomas. Additionally, 1q gained tumors showed elevated expression of ETV3, an E-twenty-six factor gene located on chromosome 1q.Taken together we describe a subgroup-specific impact of telomerase reactivation on disease progression in pediatric ependymoma and provide preliminary evidence for the involved molecular mechanisms.
000128032 536__ $$0G:(DE-HGF)POF3-319H$$a319H - Addenda (POF3-319H)$$cPOF3-319H$$fPOF III$$x0
000128032 588__ $$aDataset connected to CrossRef, PubMed,
000128032 7001_ $$aLötsch, Daniela$$b1
000128032 7001_ $$aSpiegl-Kreinecker, Sabine$$b2
000128032 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b3$$udkfz
000128032 7001_ $$aNeumayer, Katharina$$b4
000128032 7001_ $$aKorbel, Pia$$b5
000128032 7001_ $$aAraki, Asuka$$b6
000128032 7001_ $$aBrandstetter, Anita$$b7
000128032 7001_ $$aMohr, Thomas$$b8
000128032 7001_ $$0P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aHovestadt, Volker$$b9$$udkfz
000128032 7001_ $$0P:(DE-He78)082dd3179733e3e716a58eb90f418a78$$aChavez, Lukas$$b10$$udkfz
000128032 7001_ $$aKirchhofer, Dominik$$b11
000128032 7001_ $$aRicken, Gerda$$b12
000128032 7001_ $$aStefanits, Harald$$b13
000128032 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b14$$udkfz
000128032 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b15$$udkfz
000128032 7001_ $$aDieckmann, Karin$$b16
000128032 7001_ $$aAzizi, Amedeo A$$b17
000128032 7001_ $$aCzech, Thomas$$b18
000128032 7001_ $$aFilipits, Martin$$b19
000128032 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b20$$udkfz
000128032 7001_ $$aPeyrl, Andreas$$b21
000128032 7001_ $$aSlavc, Irene$$b22
000128032 7001_ $$aBerger, Walter$$b23
000128032 7001_ $$aHaberler, Christine$$b24
000128032 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/nox027$$gVol. 19, no. 9, p. 1183 - 1194$$n9$$p1183 - 1194$$tNeuro-Oncology$$v19$$x1523-5866$$y2017
000128032 909CO $$ooai:inrepo02.dkfz.de:128032$$pVDB
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)082dd3179733e3e716a58eb90f418a78$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000128032 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000128032 9131_ $$0G:(DE-HGF)POF3-319H$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000128032 9141_ $$y2017
000128032 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000128032 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128032 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2015
000128032 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128032 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128032 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128032 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128032 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128032 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128032 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128032 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2015
000128032 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000128032 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x1
000128032 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x2
000128032 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000128032 980__ $$ajournal
000128032 980__ $$aVDB
000128032 980__ $$aI:(DE-He78)B062-20160331
000128032 980__ $$aI:(DE-He78)G380-20160331
000128032 980__ $$aI:(DE-He78)B060-20160331
000128032 980__ $$aI:(DE-He78)L101-20160331
000128032 980__ $$aUNRESTRICTED